Dubai Investments Buys Back Stake of Globalpharma from Sanofi
Dubai Investments (DFM: DIC) announced last week that it will purchase an additional 66% stake in pharmaceutical company Globalpharma, giving it full ownership of the company. Dubai Investments invest in a number of sectors, including healthcare and education in the UAE and the Middle East. You’re not alone if this story sounds familiar. Sanofi (NASDAQ: SNY) purchased a 66% majority stake of Globalpharma from Dubai Investments in 2014, leaving the latter company only a 34% minority stake up until last week’s deal. Globalpharma manufactures and commercializes generic medicines, and Sanofi integrated Globalpharma as its platform to manufacture and promote the generics portfolio... Read More »
October 2018 Healthcare Deal Spending Breaks Even
Spending on healthcare deals in the month of October didn’t match the surge in deal volume (see separate post). At $9.4 billion, October 2018 posted a slight 4% gain over September, but was 25% lower than the $12.6 billion spent in October 2017. Of course, we can only go by disclosed prices, and several transactions that did not disclose financial terms would probably boost the month’s total by at least a few billion dollars. H.I.G. Capital’s acquisition of Correct Care Solutions, is a case in point. Co-owners Audax, GTCR and Frazier Healthcare sold Correct Care, which provides medical and behavioral health services for nearly 250,000 patients in 38 U.S. states and in Australia. Only... Read More »
Biotechnology Gets the Usual January Boost
The Biotechnology sector roared to life in 2017, posting a record 209 transactions. That’s 20% higher than the 174 deals announced in 2016. The previous record for the sector was set in 2009, with 193 transactions announced in the space. Spending for those 209 deals in 2017 didn’t set new records, but did post an impressive $54.5 billion in disclosed prices. That’s 283% higher than the $18.6 billion recorded in all of 2016, but not close to the secctor’s annual spending record of $93.9 billion, set in 2008. Every January, the Biotechnology Showcase is held in San Francisco, concurrent with the J.P. Morgan Healthcare conference. And every January, this sector sees... Read More »Sanofi Rationalizes Its Vaccine Portfolio
Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including its related contract with the Center for Disease Control (CDC). In 2016, Sanofi generated $5.04 billion in net sales from its vaccine products. Its influenza vaccine unit was the second largest contributor to this total, accounting for $1.7 billion in net sales that year, a record year for Sanofi’s influenza campaign. Sanofi Pasteur, the... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
